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LETTERS TO THE EDITOR
Cytokines and Acute Cardiac Rejection--the
Unfulffied Promise?
The interesting report of Fyfe et al . (1) on coronary sinus sampling
of cytokines after heart transplantation is based on the hypothesis
that if cytokines were being actively produced within the graft, there
should be a significant difference between cytokine concentration
measured from the coronary sinus and that obtained during simul-
taneous sampling from the superior vena cava, The current theory
on the sequence of immune recognition of a foreign antigen, its
pwwrw,ttion to the T lymphocyte receptor and subsequent activa-
tion of lymphocytes proposes a process driven by various cytokines
stimulating the invasion of cytotoxic T cells into the graft and the
inflammatory changes seen on endomyocardial biopsy (2,3) . We and
others (4,5) have previously reported a temporal relation between
the sequences of elevated soluble interleukin-2 receptor levels and
subsequent significant cardiac allograft rejection spanning a number
of days, We suggest that the peak levels of immune activators may
either predate the histologic changes or relate to the early develop-
ment of rejection . It is therefore not surprising that Fyfe et al . (1)
were unable to demonstrate any direct correlation between concur-
rent cytokine levels and biopsy grade .
Their secondary hypothesis regarding the measurement of cyto-
kine concentration in the coronary sinus or superior vena cava or
the difference between these two concentrations and its correlation
with the severity of rejection on myocardial biopsy any be similarly
flawed. Furthermore, the investigators give no breakdown of the
various rejection grades obtained. Were higher levels noted in the
higher rejection grades? This would be hard to interpret given the small
sample
SIZe .
Fyfe et al, give no indication of how they deemed cytokine
activity to be "baseline" when they compared cytokine concentra-
tions measured during the absence of rejection with those measured
during an episode of rejection in each patient . There is a striking
augmentation of cytokine release after acute tissue injury due to a
surgical procedure, as well as after bacterial and viral infection (0) ;
if blood specimens are taken during this time, the sampling will be
invalidated and the levels of cytokines potentially very high . The
harvesting of endomyocardial biopsy tissue as part of a routine
surveillance endomyocardial biopsy that shows acute rejection may
not reflect the level of cytokine activation that may have been
present well before the detection of an abnormality on routine
surveillance endomyocardial biopsy . The peak levels of various
immune markers may well predate the histologic changes or relate to
the early development of rejection and could therefore explain the
poor relation between simultaneous interleukin-2 receptor levels
and allograft rejection (2,4) . The rejection process itself may have
been present for some time before biopsy, when cytokine activation
may have been at its highest ; at the time of taking the blood samples
the rejection process may even he in a state of resolution, or
cytokine production in a state of exhaustion . The histologic changes
seen at the time of acute rejection, although specific, probably are a
relatively late reflection of immune activation .
The recent development of various immune specific monoclonal
antibodies (7,8) provides great help in the interpretation of the role
of cytokines and offers exciting alternatives to the current immuno-
suppressive armamentarium for the treatment of significant rejec-
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tion. The approach of Fyfe et al . (1) potentially creates unjustified
prejudice against these agents, and we suggest that the utility of
cytokine monitoring in solid organ transplantation requires serial
collection of samples, with detailed reference to the level of immu-
nosuppression, tissue injury and so forth, taking place in the weeks
preceding sampling to best interpret levels .
STEPHEN H. JENNISON, BSc, MRCP, FOP
AARON G. WESP, MD
LFSLIE W. MILLER, MD
Heart Fallurelffeart Transplant Program
Saint Louis University Medical Center
3635 Vista Avenue at Grand Boulevard
Saint Louis, Missouri 63116
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Reply
The points raised by Jennison et al . are interesting and I think
adequately covered in our discussion . Our hypothesis that coronary
sinus cytokine levels represent a cardiac source are subject to the
caveats mentioned in our report and not by Jennison et al . : 1)
penetration from the interstitial space ; 2) coronary blood flow
(known to be increased in heart transplant patients both at baseline
and especially during rejection [I]) ; and 3) clearance of the cytokine
from the serum . Interleukin-2 (IL-2) receptors, which appear to be
the major focus of the letter of Jennison et al ., have a relatively long
half-life in serum, which may make it impossible to detect differ-
ences between the coronary sinus and superior vena cava . In our
cases, as explained in the Discussion . IL-2 receptor levels were
artificially elevated by antithymocyte preparations, which may have
obscured any potential differences .
The suggestion of Jennison et al . that cytokine release predates
rejection is shown in our Figure 7 . Similar profiles were seen for
interleukin-4 and tumor necrosis factor-alpha. What length of time
should we allow to elapse before we consider a particular cytokine
release to be associated with a specific rejection episode? Only
careful collection of multiple samples over time will allow this
question to be answered . We cannot ethically justify performing this
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procedure on our patients for purely scientific reasons outside the
context of indicated biopsies .
All rejection episodes were International Society in Heart and
Lung Transplantation grade 3A and greater, and baseline was
considered grade 0 to 1 . Blood samples were not taken during
surgery and there was no evidence of active viral infection at the
time of cytokine measurement . Active infection was an exclusion
criterion for inclusion of data into the study .
We believe that our study does not prejudice the further devel-
opment of monoclonal antibodies, mainly because Jennison et al .
misunderstand the aim of our study . This was an observational
study to examine which cytokines are being released and only
secondarily to correlate these cytokines with rejection . The study
does not have the power to address the latter question, We should
have stated that there is no obvious relation between a particular
cytokine and rejection ; this does not imply that a relation does not
exist . In fact, our Figure 7 suggests that a relation may well exist .
We believe that documenting that a number of cytokines other than
IL-2 receptor (Ref . 3 to 8 of Dennison et al .) are being release(] from
the cardiac allograft (and not irom some unknown peripheral site)
provides exciting new potential therapeutic options .
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Pulmonary Embolism After CardWc Surgery
I was impressed by the unusually high incidence of pulmonary
embolism after cardiac operations in the report by Josa and associ-
ates (1) . Their retrospective data led logically to the conclusion that
the incidence of pulmonary embolism in the patients undergoing
coronary artery bypass grafting (3 .9%) is higher than that (3%)
reported by Kakkar et al . (2) in a prospective study of patients
undergoing general surgical operations . However, I feel uncomfort-
able with their conclusion because we recently reported different
results (3) on the same issue .
In our report (3), we reviewed the clinical records of 4,393
patients who underwent cardiac surgery requiring cardiopulmonary
bypass at a large university hospital between January 1984 and
December 1988 . Of these, only 13 patients developed venous
thromboembolism postoperatively . There were eight cases of deep
vein thrombosis and five of pulmonary embolism . Three of the
patients with pulmonary embolism underwent coronary artery by-
pass grafting and two had aortic valve replacement . Pulmonary
embolism accounted for the death of one patient . Follow-up data
were available in all patients and averaged 38 ± 5 .6 months (range 2
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Figure 1 . Survival rate and incidence of deep vein thrombosis
(DVT) and pulmonary embolism (PE) in 4,393 patients who under-
went cardiac surgery requiring cardiopulmonary hospital at a large
university hospital between January 1984 and December 1988 .
Reprinted, with permission, from Canver and Fiedler (3) .
to 72) . Actuarial survival at 5 years was 92% after a cardiac
operation (Fig . 1) .
Our observations agree with their proposed risk factors of
prolonged immobility, obesity and previous deep vein thrombosis .
However, the incidence of venous thromboembolism after open
heart surgery was 0 .3% in our series (3) . The increasing use of
intravenous and oral anticoagulant agents before open heart surgery
and the routine use of platelet suppressant therapy may offer
possible explanations for the observed low occurrence of postoper-
ative pulmonary embolism in this subset of patients . Based on our
experience, it appears that the 3 .9% incidence of pulmonary embo-
lism among cardiac surgical patients is extremely high .
In many cases of pulmonary embolism occurring after general
surgical operations, deep vein thrombosis is the most common
source for dislodgment of a clot in the pulmonary circuit . It is
unclear why the incidence of deep vein thrombosis is very low iii
pulmonary embolism cases in the series of Josa and associates (I) .
This discrepancy requires explanation .
Limitations of retrospective studies on this complex issue em-
phasize the need for a randomized prospective study to investigate
the true incidence of venous thromboembolic complications after
cardiac surgery .
CHARLES C. CANVER, MD, FACC
Division of Cardiothoracic Surgery
University of
Wisconsin-Madison Medical School
H41352, Clinical Science Center
600 Highland Avenue
Madison, Wisconsin 53792
References
I . Josa M, Siouffi SY . Silverman AB . Barsamian EM
. Khuri SF . Sharma GvRK.
Pulmonary embolism after cardiac surgery . I Am Coll Cardiol 1"3
;21 :990-6 .
2 . Kakkar VV
. Howie CT . Flanc C . Clarke MB . Natural history of postoperative deep
vein thrombosis . Lancet 1%9 ;2
:230-2 .
3 . Canver CC . Fiedler RC
. Venous thromboembolic complications after open hear ,
surgery . Vase Sorg 1992 :26 :21 13- 7 .
Reply
Canver's letter raises two important issues : the incidence of deep
vein thrombosis and pulmonary embolism after cardiac surgery .
With respect to the first, it was not the aim of our study to determine
the incidence of deep vein thrombosis in patients undergoing cardiac
surgery . Although deep vein thrombosis precedes pulmonary em-
bolism, it is usually asymptomatic and can be detected only by
